Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Gregory S. Blank
Advertisement
Gregory S. Blank is the director of late-stage purification at Genentech, Inc.
Articles by Gregory S. Blank
Advertisement
Latest Updated Articles
Purification Strategies to Process 5 g/L Titers of Monoclonal AntibodiesPublished: March 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
